Skip to content
Triangle logo TriangleGet started
← Study library

NCT00002757 · CITED IN SOURCE DOCUMENTS

TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE3
Status at capture
COMPLETED
Registry last update
2014-07-24

RATIONALE: Less intensive therapy may attain in the same results as intensive therapy in children with non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to study the effectiveness of less intensive therapy for children who have non-Hodgkin's lymphoma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
DISEASE CHARACTERISTICS: * One of the following diagnoses: * Newly diagnosed B-cell non-Hodgkin's lymphoma in Revised European-American Lymphoma (REAL) categories II 9, 10, and 11, i.e.: * Diffuse large cell * Burkitt's * High-grade B-cell, Burkitt's-like * L3 leukemia with greater than 5% blasts in bone marrow * No anaplastic large cell Ki1-positive lymphomas * Immunophenotype and Murphy stage required prior to randomization PATIENT CHARACTERISTICS: Age: * Over 6 months to under 21 years * Maximum age 18 years in France and the United Kingdom Other: * No congenital immunodeficiency * No prior organ transplantation * No prior malignancy * Not HIV positive * Available for at least 36 months of follow-up PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No prior chemotherapy Endocrine therapy: * Steroids initiated no more than 72 hours prior to entry allowed * Bone marrow and cerebrospinal fluid examination required prior to steroids Radiotherapy: * Emergency radiotherapy initiated no more than 72 hours prior to entry allowed Surgery: * Not specified
healthy Volunteers
false
maximum Age
20 Years
sex
ALL
std Ages
  1. CHILD
  2. ADULT
Treatment arms and interventions
arm Groups
  1. description
    All resected stage I and Abdominal stage II only. All Group A patients will be treated with two cycles of COPAD and will be followed in a confirmatory study of the current result of nearly 100% cure rate.
    intervention Names
    1. Biological: filgrastim
    2. Drug: cyclophosphamide
    3. Drug: doxorubicin hydrochloride
    4. Drug: prednisone
    5. Drug: vincristine sulfate
    label
    Group A
    type
    ACTIVE_COMPARATOR
  2. description
    Non resected stage I \& II, stage III \& st IV (CNS - ve, BM \< 25%). Patients with bulky disease are at risk from metabolic complications secondary to tumor lysis syndrome. Vigorous measures should be taken to minimise the risk of this. Prior to any chemotherapy being administered intravenous hydration fluids should be given run at a rate of 3000 mls/m2/day. Alkalinisation may be necessary Pay close attention to fluid balance and continue hydration fluids after the administration of COP for as long as the risk of tumour lysis persists.
    intervention Names
    1. Biological: filgrastim
    2. Drug: cyclophosphamide
    3. Drug: doxorubicin hydrochloride
    4. Drug: methotrexate
    5. Drug: prednisolone
    6. Drug: prednisone
    7. Drug: therapeutic hydrocortisone
    8. Drug: vincristine sulfate
    label
    Group B
    type
    ACTIVE_COMPARATOR
  3. description
    Bone marrow \> 25% but CNS negative Patients with bulky disease are at risk from metabolic complications secondary to tumor lysis syndrome. Vigorous measures should be taken to minimize the risk of this. Intravenous hydration fluids should be given prior to chemotherapy. Alkalinisation may be necessary. Monitor fluid balance and continue hydration fluids after the administration of COP for as long as the risk of tumor lysis persists
    intervention Names
    1. Biological: filgrastim
    2. Drug: cyclophosphamide
    3. Drug: cytarabine
    4. Drug: doxorubicin hydrochloride
    5. Drug: etoposide
    6. Drug: methotrexate
    7. Drug: prednisolone
    8. Drug: therapeutic hydrocortisone
    9. Drug: vincristine sulfate
    label
    Group C
    type
    ACTIVE_COMPARATOR
interventions
  1. arm Group Labels
    1. Group A
    2. Group B
    3. Group C
    name
    filgrastim
    other Names
    1. G-CSF
    2. Neupogen
    3. NSC-614629
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Group A
    2. Group B
    3. Group C
    name
    cyclophosphamide
    other Names
    1. NSC-26271
    type
    DRUG
  3. arm Group Labels
    1. Group C
    name
    cytarabine
    other Names
    1. NSC-63878
    type
    DRUG
  4. arm Group Labels
    1. Group A
    2. Group B
    3. Group C
    name
    doxorubicin hydrochloride
    other Names
    1. NSC-123127
    type
    DRUG
  5. arm Group Labels
    1. Group C
    name
    etoposide
    other Names
    1. VP16
    2. NSC-141540
    type
    DRUG
  6. arm Group Labels
    1. Group B
    2. Group C
    name
    methotrexate
    other Names
    1. NSC-740
    type
    DRUG
  7. arm Group Labels
    1. Group B
    2. Group C
    name
    prednisolone
    other Names
    1. NSC-10023
    type
    DRUG
  8. arm Group Labels
    1. Group A
    2. Group B
    name
    prednisone
    other Names
    1. NSC-10023
    type
    DRUG
  9. arm Group Labels
    1. Group B
    2. Group C
    name
    therapeutic hydrocortisone
    other Names
    1. HYDROCORTISONE SODIUM SUCCINATE
    2. NSC-10483
    type
    DRUG
  10. arm Group Labels
    1. Group A
    2. Group B
    3. Group C
    name
    vincristine sulfate
    other Names
    1. VCR
    2. NSC-675574
    type
    DRUG
Study design
allocation
RANDOMIZED
primary Purpose
TREATMENT
Enrollment
count
1148
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Minimum time to death from any cause, relapse, or progressive disease, measured from the beginning of chemotherapy. Failure to respond to initial COP therapy, and biopsy positive residual disease at the third evaluation are not considered failures in this definition. However, death, relapse or disease progression following protocol mandated therapy intensification after these occurrences will be considered failures. In addition, biopsy positive residual disease at the completion of intensification is considered an event.
    measure
    Event Free Survival
secondary Outcomes
  1. description
    Time to death from any cause, measured from the time of randomization in Groups B and C.
    measure
    Conditional Survival
  2. description
    Minimum time to death from any cause, progressive disease before the third evaluation, no CR at the third evaluation, relapse after the third evaluation, measured from the beginning of chemotherapy. Failure to respond to COP therapy in Groups B and C is not considered a treatment failure, but biopsy positive residual disease after the third evaluation are considered failures in this definition.
    measure
    Failure Free Survival
Full study description
brief Summary
RATIONALE: Less intensive therapy may attain in the same results as intensive therapy in children with non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to study the effectiveness of less intensive therapy for children who have non-Hodgkin's lymphoma.
detailed Description
OBJECTIVES: * Confirm the previously found excellent survival for low-risk patients (Group A) with B-cell lymphoma/leukemia treated with the LMB 89 regimen. * Verify that good event-free survival is retained in intermediate-risk patients (Group B) when the dose of cyclophosphamide (CTX) or the number of CTX-containing regimens is reduced. * Verify that good event-free survival is retained in high-risk patients (Group C) despite reduction in doses during consolidation therapy and a reduced number of maintenance courses, and, for patients with CNS involvement, additional intravenous and intrathecal methotrexate in place of cranial irradiation. * Monitor survival and event-free survival of all patients registered prior to the first chemotherapy course. * Compare the survival and event-free survival of Group C patients with CNS involvement against results from those treated on the LMB 89 study. * Compare event-free survival and survival of patients with large cell and Burkitt's and Burkitt's-like lymphoma. * Monitor the long-term toxicity in patients treated on this study, including fertility, cardiotoxicity, and secondary malignancy. * Characterize further the biology of childhood small non-cleaved cell lymphoma with respect to drug resistance (i.e., topoisomerase II and MDR activity), viral association (i.e., Epstein-Barr virus, human immunodeficiency virus, human herpesvirus 6), and specific breakpoint translocations (i.e., IgH and C-myc) per companion study CCG-B944. * Characterize further the biology of childhood mature B-cell lymphoma per UKCCSG studies. OUTLINE: This is a randomized study. Patients are stratified according to participating group (UKCCSG vs SFOP vs CCG), histology (large cell vs small non-cleaved cell), risk group (Group A vs Group B vs Group C). Stage III Group B patients are further stratified according to Murphy stage (stages I/II vs III vs III/IV) and by LDH (less than twice normal vs twice normal or higher). Group C patients are further stratified based on presence of CNS disease (yes vs no). Patients with resected stage I and resected abdominal-only stage II disease are treated on the Group A Regimen. Patients with unresected stage I/II, stage III, or CNS-negative stage IV disease with fewer than 25% blasts in bone marrow are treated on the Group B Regimen. Patients with 25% or more blasts in bone marrow or with CNS involvement (i.e., L3 blasts in CSF, cranial nerve palsy, clinical spinal cord compression, isolated intracerebral mass, or parameningeal cranial or spinal extension) are treated on the Group C Regimen. The following acronyms are used: * ARA-C Cytarabine, NSC-63878 * CF Leucovorin calcium, NSC-3590 * COP CTX/VCR/PRED (or PRDL) * COPAD CTX/VCR/PRED (or PRDL)/DOX * COPADM CTX/VCR/PRED (or PRDL)/DOX/MTX * CTX Cyclophosphamide, NSC-26271 * CYM ARA- C/MTX * CYVE ARA-C/VP-16 * DOX Doxorubicin, NSC-123127 * G-CSF Granulocyte Colony-Stimulating Factor (Amgen), NSC-614629 * HC Hydrocortisone, NSC-10483 * HD High Dose * MTX Methotrexate, NSC-740 * PRDL Prednisolone, NSC-9900 * PRED Prednisone, NSC-10023 * TIT Triple Intrathecal Chemotherapy (IT MTX/IT HC/IT ARA-C) * VCR Vincristine, NSC-67574 * VP-16 Etoposide, NSC-141540 Group A Regimen (Low-Risk Patients) * Induction: Patients receive COPAD: VCR IV on days 1 and 6, oral PRED (or IV) twice daily on days 1-5, then tapered over 3 days, CTX IV over 15 minutes every 12 hours on days 1-3, and DOX IV over 6 hours on day 1 starting after the first CTX dose. G-CSF SC is administered until hematopoietic recovery beginning on day 7. Patients receive a second course beginning on day 21. Group B Regimen (Intermediate-Risk Patients) * Induction 1: Patients receive CTX IV over 15 minutes on day 1, VCR IV on day 1, and oral PRED on days 1-7, and MTX IT and HC IT on day 1. Patients with responding disease proceed with COPADM. Patients with no response proceed to treatment on arm I of the Group C Regimen. * COPADM 1: Patients receive VCR IV on day 8, oral PRED twice daily on days 8-12, then tapered over 3 days, MTX IV over 3 hours on day 8, oral CF every 6 hours for 12 doses beginning 24 hours after start of MTX, CTX IV over 15 minutes every 12 hours on days 9-11, and DOX IV over 6 hours on day 9 beginning after the first CTX dose. G-CSF is administered as in the Group A Regimen. MTX IT and HC IT are given on days 9 and 13. * Group B patients are randomized to 1 of 4 treatments following recovery and disease assessment: Arm I: * Induction 2 (begins no sooner than 16 days after start of COPADM 1): Patients receive COPADM 2 according to the same schedule as in COPADM 1 in Induction 1 except CTX is increased. G-CSF is administered as in the Group A Regimen. Patients receive MTX IT and HC IT on days 2 and 6. * Consolidation: Patients receive CYM: MTX IV over 3 hours on day 1, oral CF every 6 hours for a maximum of 12 doses beginning 24 hours after the start of MTX, and ARA-C IV over 24 hours on days 2-6. Patients receive TIT: MTX IT on day 2, HC IT on days 2 and 7, and ARA-C IT on day 7. * Response is assessed upon recovery with resection of residual masses. If histology is negative patients proceed to a second course of CYM. If histology is positive patients proceed to CYVE on arm I of the Group C Regimen. * Maintenance: Patients receive COPADM 3 as in COPADM 1 in Induction 1, except CTX IV is administered over 30 minutes on days 2 and 3, and MTX IT and HC IT are administered on day 2. Arm II: * Induction 2: Patients receive COPADM 2 as in arm I of the Group B Regimen. G-CSF is administered as in the Group A Regimen. MTX IT and HC IT are administered as in Induction 1. * Consolidation: Patients receive CYM, TIT, and response assessment as in arm I of the Group B Regimen. * Maintenance: Patients receive no maintenance therapy. Arm III: * Induction 2: Patients receive COPADM 2 as in COPADM 1 in Induction 1. G-CSF is administered as in the Group A Regimen. Patients receive MTX IT and HC IT as in Induction 1. * Consolidation: Patients receive CYM, TIT, and response assessment as in arm I of the Group B Regimen. * Maintenance: Patients receive COPADM 3 as in arm I of the Group B Regimen. Patients receive MTX IT and HC IT on day 2. Arm IV: * Induction 2: Patients receive COPADM 2 as in COPADM 1 in Induction 1. G-CSF is administered as in the Group A Regimen. Patients receive MTX IT and HC IT as in Induction 1. * Consolidation: Patients receive CYM, TIT, and response assessment as in arm I of the Group B Regimen. * Maintenance: Patients receive no maintenance therapy. Group C Regimen (High-Risk Patients) * Induction: Patients receive COP as in Induction 1 of the Group B Regimen, TIT on days 1, 3, and 5, and oral CF every 12 hours on days 2 and 4. Tumor response is evaluated on day 7 and treatment decisions are made as in Induction 1 of the Group B Regimen. Patients receive COPADM 1 as in COPADM 1 in Induction 1 of the Group B Regimen except HD MTX IV is given over 4 hours on day 1. G-CSF is administered as in the Group A Regimen. TIT is given on days 2, 4, and 6. Patients receive COPADM 2 as in COPADM 2 in arm I of the Group B Regimen, Induction 2 except HD MTX IV is given over 4 hours on day 1. G-CSF is administered as in the Group A Regimen. Patients receive TIT on days 2, 4, and 6. * Patients are randomized to 1 of 2 treatment arms upon recovery and disease assessment: Arm I: * Consolidation: Patients receive CYVE: ARA-C IV on days 1-5, and VP-16 IV over 2 hours on days 2-5. G-CSF is administered as in the Group A Regimen. For patients with CNS disease: MTX IT and HC IT on day 1, 6 hours prior to initiation of ARA-C, HD MTX IV over 4 hours, about day 18, oral CF every 6 hours for a maximum of 12 doses, beginning 24 hours after starting MTX, and TIT prior to beginning CF. * Response is assessed upon recovery with resection of residual masses. Patients with a complete response receive a second course of CYVE (no HD MTX/CF), beginning 1 week after HD MTX. * Maintenance (28 days between courses): * Course 1: Patients receive COPADM as in arm I Maintenance in the Group B Regimen, except HD MTX is administered as in Group C Induction, and TIT is given on day 2 replacing MTX IT and HC. * Course 2: Patients receive CYVE: ARA-C IV every 12 hours on days 1-5, and VP-16 IV over 90 minutes on days 1-3. * Course 3: Patients receive COPAD as in Group B Induction 1, except CTX IV is administered over 30 minutes on days 1 and 2. * Course 4: Patients receive treatment identical to Course 2. Arm II: * Consolidation: Patients receive Mini-CYVE: ARA-C IV on days 1-5, and VP-16 IV over 1 hour on days 2-5. G-CSF is administered as in the Group A Regimen. For patients with CNS disease: MTX IT and HC IT as in arm I in the Group C Regimen, and HD MTX, CF, and TIT as in arm I in the Group C Regimen. * Response is assessed upon recovery with resection of residual masses. Patients with a complete response receive a second course of CYVE (no HD MTX and CF) beginning 1 week after HD MTX. * Maintenance: Patients receive COPADM and TIT as in arm I of the Group C Regimen in Course 1 for 1 course only. Patients are followed every 3 months for 6 months, every 6 months for 2.5 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 900 patients will be accrued for this study within 5 years. Yearly accrual is expected to be 20 Group A patients, 115 Group B patients, and 45 Group C patients.
Source references
references
  1. citation
    Lones MA, Raphael M, Perkins SL, Wotherspoon A, Auperin A, Terrier-Lacombe MJ, Sposto R, Weston C, Gerrard M, Patte C, Cairo MS, McCarthy K. Mature B-cell lymphoma in children and adolescents: International group pathologist consensus correlates with histology technical quality. J Pediatr Hematol Oncol. 2006 Sep;28(9):568-74. doi: 10.1097/01.mph.0000212980.67114.a5.
    pmid
    17006262
    type
    BACKGROUND
  2. citation
    Cairo MS, Sposto R, Gerrard M, Auperin A, Goldman SC, Harrison L, Pinkerton R, Raphael M, McCarthy K, Perkins SL, Patte C. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (>/= 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012 Feb 1;30(4):387-93. doi: 10.1200/JCO.2010.33.3369. Epub 2012 Jan 3.
    pmid
    22215753
    type
    RESULT
  3. citation
    Shiramizu B, Goldman S, Kusao I, Agsalda M, Lynch J, Smith L, Harrison L, Morris E, Gross TG, Sanger W, Perkins S, Cairo MS. Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report. Br J Haematol. 2011 Jun;153(6):758-63. doi: 10.1111/j.1365-2141.2011.08681.x. Epub 2011 Apr 18.
    pmid
    21496005
    type
    RESULT
  4. citation
    Nelson M, Perkins SL, Dave BJ, Coccia PF, Bridge JA, Lyden ER, Heerema NA, Lones MA, Harrison L, Cairo MS, Sanger WG. An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961. Br J Haematol. 2010 Feb;148(4):600-10. doi: 10.1111/j.1365-2141.2009.07967.x. Epub 2009 Nov 4.
    pmid
    19895612
    type
    RESULT
  5. citation
    Poirel HA, Cairo MS, Heerema NA, Swansbury J, Auperin A, Launay E, Sanger WG, Talley P, Perkins SL, Raphael M, McCarthy K, Sposto R, Gerrard M, Bernheim A, Patte C; FAB/LMB 96 International Study Committee. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Leukemia. 2009 Feb;23(2):323-31. doi: 10.1038/leu.2008.312. Epub 2008 Nov 20.
    pmid
    19020548
    type
    RESULT
  6. citation
    Gerrard M, Cairo MS, Weston C, Auperin A, Pinkerton R, Lambilliote A, Sposto R, McCarthy K, Lacombe MJ, Perkins SL, Patte C; FAB LMB96 International Study Committee. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008 Jun;141(6):840-7. doi: 10.1111/j.1365-2141.2008.07144.x. Epub 2008 Mar 26.
    pmid
    18371107
    type
    RESULT
  7. citation
    Miles RR, Raphael M, McCarthy K, Wotherspoon A, Lones MA, Terrier-Lacombe MJ, Patte C, Gerrard M, Auperin A, Sposto R, Davenport V, Cairo MS, Perkins SL; SFOP/LMB96/CCG5961/UKCCSG/NHL 9600 Study Group. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group. Pediatr Blood Cancer. 2008 Sep;51(3):369-74. doi: 10.1002/pbc.21619.
    pmid
    18493992
    type
    RESULT
  8. citation
    Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, Weston C, Perkins SL, Raphael M, McCarthy K, Patte C; FAB LMB96 International Study Committee. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007 Apr 1;109(7):2736-43. doi: 10.1182/blood-2006-07-036665.
    pmid
    17138821
    type
    RESULT
  9. citation
    Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS; FAB/LMB96 International Study Committee. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007 Apr 1;109(7):2773-80. doi: 10.1182/blood-2006-07-036673.
    pmid
    17132719
    type
    RESULT
  10. citation
    Goldman S, Gerrard M, Sposto R, et al.: Excellent results in children and adolescents with isolated mature B-acute lymphoblastic leukemia (B-ALL) (Burkitt): report from the French-American-British (FAB) international LMB study FAB/LMB96. [Abstract] Blood 106 (11): A-234, 2005.
    type
    RESULT
  11. citation
    Poirel HA, Heerema NA, Swansbury J, et al.: In pediatric mature B-cell non Hodgkin's lymphoma (NHL), complex karyotype or del(13q) are linked prognostic factors in Burkitt lymphoma (BL) while 8q24/c-myc rearrangement is associated with a strong adverse effect in diffuse large B-cell lymphoma (DLBCL). [Abstract] Blood 106 (11): A-1905, 2005.
    type
    RESULT
  12. citation
    Lones M, Perkins S, Sposto R, et al.: T-cell-rich large B-cell lymphoma (TCRLBCL) in children and adolescents treated on a B-large cell lymphoma trial: a report from the Children's Cancer Group (CCG) study CCG-5961. [Abstract] Ann Oncol 13(suppl 2): A-137, 45, 2002.
    type
    RESULT
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-c3f88007f5fd98462adf
      requested nct id
      NCT00002757
      primary nct id
      NCT00002757
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      f1f1a2b5d12aecd8245482e171eae02ca47aedde6097c4c21b97855f62bb55e0
      payload sha256
      2cf5842c3282c7d0b633a3f7423a1a191f4b6f253c86aa9525ab5225fbff5927
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-c3f88007f5fd98462adf
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00002757
      occurrences
      1. context exact
        > Patients who received two cycles of multiagent chemotherapy, without intrathecal chemotherapy or rituximab, had excellent outcomes (<a href="/clinicaltrials/NCT00002757">COG-C5961 [FAB/LMB-96]</a>).[<a href="#cit/section_6.27">27</a>][<a href="/Common/PopUps/popDefinition.aspx?id=810033&amp;version=HealthProfessional&amp;lang
        end
        181956
        exact text
        NCT00002757
        start
        181945
      2. context exact
        studies demonstrated that omission of craniospinal irradiation, even in patients presenting with CNS disease, does not affect outcome (<a href="/clinicaltrials/NCT00002757">COG-C5961 [FAB/LMB-96]</a> and NHL-BFM-90 [GER-GPOH-NHL-BFM-90]).[<a href="#cit/section_6.21">21</a>-<a href="#cit/section_6.23">23</a>,<a href="#cit/section
        end
        183650
        exact text
        NCT00002757
        start
        183639
      3. context exact
        cology Group (COG) pilot study (<a href="/clinicaltrials/NCT00057811">COG-ANHL01P1</a>) added rituximab to baseline chemotherapy with <a href="/clinicaltrials/NCT00002757">FAB/LMB-96</a> therapy in patients with stage III and stage IV B-cell NHL.[<a href="#cit/section_6.30">30</a>-<a href="#cit/section_6.32">32</a>]; [<a href="#
        end
        184569
        exact text
        NCT00002757
        start
        184558
      4. context exact
        c Oncology Group.</td> </tr> </TFoot> <tbody> <tr> <td rowspan="5"><a href="/clinicaltrials/NCT00002757">COG-C5961</a> (FAB/LMB-96) [<a href="#cit/section_6.22">22</a>,<a href="#cit/section_6.27">27</a>] COG-ANHL01 [<a href="#cit/section_6.31">31</a>,<a href="#ci
        end
        188586
        exact text
        NCT00002757
        start
        188575
      5. context exact
        ex="-1">Pediatric and adolescent patients with stage III primary mediastinal large B-cell lymphoma fared significantly worse on the <a href="/clinicaltrials/NCT00002757">FAB/LMB-96 (NCT00002757)</a> study, with a 5-year EFS rate of 66%, compared with 85% for adolescents with nonmediastinal diffuse large B-cell lymphoma.[<a hre
        end
        228276
        exact text
        NCT00002757
        start
        228265
      6. context exact
        lescent patients with stage III primary mediastinal large B-cell lymphoma fared significantly worse on the <a href="/clinicaltrials/NCT00002757">FAB/LMB-96 (NCT00002757)</a> study, with a 5-year EFS rate of 66%, compared with 85% for adolescents with nonmediastinal diffuse large B-cell lymphoma.[<a href="#cit/section_6.92">92<
        end
        228301
        exact text
        NCT00002757
        start
        228290
      7. context exact
        e lower than those in other studies that treated patients with DA-EPOCH-R and were not statistically different from the results of the <a href="/clinicaltrials/NCT00002757">FAB/LMB-96 (NCT00002757)</a> trial, when a Burkitt lymphoma therapy was used. </li><li>The ability to dose escalate and the adverse events were similar to wha
        end
        231288
        exact text
        NCT00002757
        start
        231277
      8. context exact
        er studies that treated patients with DA-EPOCH-R and were not statistically different from the results of the <a href="/clinicaltrials/NCT00002757">FAB/LMB-96 (NCT00002757)</a> trial, when a Burkitt lymphoma therapy was used. </li><li>The ability to dose escalate and the adverse events were similar to what has been reported in ad
        end
        231313
        exact text
        NCT00002757
        start
        231302
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/fd36e5abb88f40b91c.html
      source file sha256
      f1f1a2b5d12aecd8245482e171eae02ca47aedde6097c4c21b97855f62bb55e0
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:22:02.430571+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      82ec317f50f4df507988e345c98b7f250d282967704c0ba2eddd7b442373575f
      source title
      Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: April 17, 2025
        datetime
        2025-04-17T12:00:00Z
        display
        April 17, 2025

    Preserved source evidence · Not medical advice